Personalized mRNA therapy shows early promise against melanoma in trial
TL;DR Summary
An experimental, tumor-genome–targeted mRNA therapy developed by Moderna and Merck, when combined with Keytruda, reduced the risk of melanoma recurrence or death in an ongoing clinical trial, signaling a potential new precision approach for aggressive skin cancer.
- This innovation saved lives in the pandemic. Now it’s showing strength against cancer. The Washington Post
- Benefit from Moderna’s skin cancer immunotherapy endures statnews.com
- Moderna, Merck Report Positive Results From Cancer-Vaccine Study The Wall Street Journal
- Moderna, Merck & Co. cancer vaccine combo holds edge over Keytruda at five-year mark FirstWord Pharma
- Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melano Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
18 min
vs 18 min read
Condensed
99%
3,544 → 37 words
Want the full story? Read the original article
Read on The Washington Post